Securities code: Thalys Medical Technology Group Corporation(603716) securities abbreviation: Thalys Medical Technology Group Corporation(603716) Announcement No.: 2022017
Bond Code: 113601 bond abbreviation: Saili convertible bond
Thalys Medical Technology Group Corporation(603716)
Announcement of abnormal fluctuations in stock trading
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips:
Thalys Medical Technology Group Corporation(603716) (hereinafter referred to as “the company”) shares traded for three consecutive years
The cumulative deviation of closing price increase in the last trading days (March 10, March 11 and March 14, 2022) exceeded
20%. According to the relevant provisions of the trading rules of Shanghai Stock Exchange, it belongs to abnormal fluctuation of stock trading
Shape.
After the company’s self-examination and sent a letter to the controlling shareholder saihai technology and the actual controller Mr. Wen Wei for verification,
Saihai technology plans to introduce strategic investors and improve the corporate governance structure by means of agreement transfer, and the relevant matters are implemented
There is still great uncertainty whether to implement it or not. The controlling shareholder and the actual controller have no material assets that should be disclosed but not disclosed
Big message.
At present, the company’s production and operation activities are normal, and there is no major adjustment in the market environment and industrial policies
All subordinate businesses of the company are carried out normally, and the internal production and operation order is normal. According to the company in January 2022
According to the announcement on performance loss in 2021 disclosed on the 29th, the company expects to belong to the shareholders of Listed Companies in 2021
The net profit after deducting non recurring profits and losses is expected to be – 18 million yuan to – 27 million yuan
In 2021, the net profit attributable to the shareholders of the listed company was – 17 million yuan to – 25 million yuan
RMB, there will be a loss (unaudited data).
The New Coronavirus antigen detection kit developed by the company has been approved by the European Union CE.
For sales in the EU market, the company has applied for but has not obtained the medical certificate issued by China’s State Drug Administration
The registration certificate of therapeutic instruments cannot be sold in the Chinese market. The company disclosed the customs declaration on January 21, 2022
Announcement on signing major daily operation contracts with wholly-owned subsidiaries of the company (Announcement No.: 2022006)
Due to the recent changes in the international situation such as the Ukrainian war, the transportation cost has risen sharply and the shipping space is tight, so the company
The first batch of export orders to Turkey have not yet started shipping.
1、 Details of stock trading (abnormal) fluctuations
The deviation of the daily closing price of the company’s shares in three consecutive trading days on March 10, March 11 and March 14, 2022 is more than 20%. According to the relevant provisions of the trading rules of Shanghai Stock Exchange, it belongs to the situation of abnormal fluctuation of stock trading.
2、 Relevant information concerned and verified by the company:
(I) production and operation
According to the company’s self inspection, the company’s production and operation activities are normal, the market environment and industrial policies have not been significantly adjusted, the production and R & D of SPD and IVD business and coagulation related production reagents under the company are carried out normally, and the internal production and operation order is normal. There are no major issues affecting the abnormal fluctuation of the company’s stock trading price, and there are no major information that should be disclosed but not disclosed.
According to the announcement on performance loss in 2021 disclosed by the company on January 29, 2022, the company expects the net profit attributable to the shareholders of the listed company in 2021 after deducting non recurring profits and losses to be – 18 million yuan to – 27 million yuan, and the net profit attributable to the shareholders of the listed company in 2021 is expected to be – 17 million yuan to – 25 million yuan, There will be a loss (unaudited data).
(II) major events
After the company’s self-examination and verification by sending a letter to the controlling shareholder saihai technology and the actual controller of the company, Mr. Wen Wei, as of the date of disclosure of the announcement, saihai technology has considered introducing institutional investors and improving the corporate governance structure, It is preparing to reduce the company’s shares through agreement transfer (relevant tips have been made in the suggestive announcement on the transfer of some shares by agreement and changes in equity by controlling shareholders (Announcement No.: 2021098) disclosed by the company on November 5, 2021), and there is still great uncertainty about the implementation of relevant matters. In addition, the company, the controlling shareholder and the actual controller of the company do not have any major information that should be disclosed but not disclosed involving the listed company, including but not limited to major asset restructuring, acquisition, debt restructuring, business restructuring, asset divestiture, asset injection, share repurchase, equity incentive, bankruptcy reorganization Major business cooperation and other major matters that have a great impact on the company’s stock trading price.
(III) media reports, market rumors and hot concepts
The New Coronavirus antigen detection kit developed by the company has been applied to the China National Drug Administration but has not yet obtained the medical device registration certificate, and is not yet available for sale in China.
The New Coronavirus antigen detection kit developed by the company has been approved by the European Union CE, and can be sold in the EU market. However, the above product certification is not exclusive to the company. There are many similar products or other testing products in the market, and the market competition is fierce.
In addition, no major events that have a significant impact on the company’s stock trading price, no media reports or market rumors that need to be clarified or responded to, and no other hot concept matters are involved.
(IV) other stock price sensitive information
According to the company’s self-examination, the company did not find any other major events that may have a great impact on the company’s share price. The controlling shareholders, actual controllers, directors, supervisors and senior managers of the company did not buy or sell the company’s shares during the abnormal fluctuation of the company’s stock trading.
3、 Relevant risk tips
(I) on March 10, March 11 and March 14, 2022, the cumulative deviation of the closing price of the company’s shares from the value has exceeded 20%. The actual fluctuation range of the stock price after excluding the overall factors of the market and the sector is large. The company reminds the majority of investors to pay attention to the trading risks in the secondary market, make rational decisions and reduce unnecessary losses.
(II) the New Coronavirus antigen detection kit developed by the company has been applied to the China National Drug Administration but has not yet obtained the medical device registration certificate, and is not yet available for sale in China. (III) the company disclosed the 2021 annual performance forecast announcement on January 29, 2022. As of the date of this announcement, there is no situation that should be corrected in the performance forecast. The forecast data of 2021 annual performance forecast is the preliminary accounting data of the financial department according to its own specialty. The specific situation is subject to the audited 2021 annual report officially disclosed by the company.
(IV) on January 21, 2022, the company disclosed the announcement on the signing of major daily operation contracts by wholly-owned subsidiaries of the company (Announcement No.: 2022006). Due to the recent changes in the international situation such as the war in Ukraine, the transportation cost has increased significantly and the shipping space is tight, so the first batch of export orders to Turkey have not been transported.
4、 Statement of the board of directors and commitments of relevant parties
The board of directors of the company confirms that as of the date of this announcement, the company has no matters that should be disclosed but not disclosed in accordance with the relevant provisions of the Listing Rules of Shanghai Stock Exchange or the planning, negotiation, intention and agreement related to such matters, and the board of directors has not been informed of the matters that should be disclosed but not disclosed in accordance with the relevant provisions of the Listing Rules of Shanghai Stock Exchange Information that may have a great impact on the stock trading price of the company.
5、 Online announcement attachment
Reply to inquiry letter on abnormal fluctuation of Thalys Medical Technology Group Corporation(603716) stock trading
It is hereby announced.
Thalys Medical Technology Group Corporation(603716) board of directors March 15, 2022
